Spots Global Cancer Trial Database for undifferentiated pleomorphic sarcoma

Every month we try and update this database with for undifferentiated pleomorphic sarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma	NCT02451943	Soft Tissue Sar...	Olaratumab Doxorubicin Placebo	18 Years -	Eli Lilly and Company
Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)	NCT06113809	Undifferentiate...	Palbociclib Pembrolizumab	12 Years -	University of Iowa
A Study of LY3435151 in Participants With Solid Tumors	NCT04099277	Solid Tumor Triple-negative... Gastric Adenoca... Head and Neck S... Cervical Carcin... High Grade Sero... Hepatocellular ... Undifferentiate... Leiomyosarcoma	LY3435151 Pembrolizumab	18 Years -	Eli Lilly and Company
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery	NCT03307616	Dedifferentiate... Recurrent Dedif... Recurrent Undif... Resectable Dedi... Resectable Undi... Undifferentiate...	Ipilimumab Nivolumab Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients	NCT04008238	Soft Tissue Sar... Undifferentiate... Epithelioid Sar... Solitary Fibrou... Hemangioendothe... Desmoplastic Ro... Synovial Sarcom...	Trabectedin	18 Years -	Institut Bergonié
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall	NCT03651375	Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito...	Sequential chem... Hypofractionate...	18 Years - 100 Years	Maria Sklodowska-Curie National Research Institute of Oncology
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma	NCT06277154	Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm...	MASCT-I Doxorubicin Ifosfamide	18 Years - 70 Years	HRYZ Biotech Co.
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas	NCT06422806	Stage III Soft ... Stage IV Soft T... Undifferentiate...	Biospecimen Col... Diagnostic Imag... Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients	NCT05961761	Soft Tissue Sar... Angiosarcoma Undifferentiate...	Propranolol Pembrolizumab	18 Years -	Herlev and Gentofte Hospital
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma	NCT02451943	Soft Tissue Sar...	Olaratumab Doxorubicin Placebo	18 Years -	Eli Lilly and Company
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma	NCT03946943	Soft Tissue Sar... Undifferentiate...	Anlotinib Toripalimab Blood Draw Tumor Specimen ...	16 Years -	The First Hospital of Jilin University
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas	NCT04055220	Bone Sarcoma Osteosarcoma Ewing Sarcoma Chondrosarcoma Undifferentiate... Leiomyosarcoma Angiosarcoma	Treatment by Re... Treatment by Pl...	12 Years -	Centre Leon Berard
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas	NCT06422806	Stage III Soft ... Stage IV Soft T... Undifferentiate...	Biospecimen Col... Diagnostic Imag... Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery	NCT03307616	Dedifferentiate... Recurrent Dedif... Recurrent Undif... Resectable Dedi... Resectable Undi... Undifferentiate...	Ipilimumab Nivolumab Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas	NCT03899805	Sarcoma Liposarcoma Leiomyosarcoma Undifferentiate...	Eribulin Pembrolizumab	18 Years -	Dana-Farber Cancer Institute
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	NCT04906876	Sarcoma Soft Tissue Sar... Metastatic Sarc... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma	Gemcitabine Docetaxel 9-ING-41	10 Years -	Brown University
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma	NCT05116800	Soft Tissue Sar... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma Osteosarcoma Ewing Sarcoma o...	Gemcitabine 9-ING-41 Docetaxel	10 Years -	Brown University
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma	NCT04420975	Leiomyosarcoma Malignant Perip... Myxofibrosarcom... Pleomorphic Rha... Resectable Dedi... Resectable Soft... Resectable Undi... Soft Tissue Fib... Spindle Cell Sa... Stage I Retrope... Stage I Soft Ti... Stage IA Retrop... Stage IA Soft T... Stage IB Retrop... Stage IB Soft T... Stage II Retrop... Stage II Soft T... Stage III Retro... Stage III Soft ... Stage IIIA Retr... Stage IIIA Soft... Stage IIIB Retr... Stage IIIB Soft... Storiform-Pleom... Synovial Sarcom... Undifferentiate... Undifferentiate... Undifferentiate... Undifferentiate... Undifferentiate...	Definitive Surg... Nanoplexed Poly... Nivolumab Radiation Thera...	18 Years -	Jonsson Comprehensive Cancer Center
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma	NCT06277154	Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm...	MASCT-I Doxorubicin Ifosfamide	18 Years - 70 Years	HRYZ Biotech Co.
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas	NCT04055220	Bone Sarcoma Osteosarcoma Ewing Sarcoma Chondrosarcoma Undifferentiate... Leiomyosarcoma Angiosarcoma	Treatment by Re... Treatment by Pl...	12 Years -	Centre Leon Berard
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma	NCT02584309	Sarcoma, Soft T... Soft Tissue Sar... Undifferentiate... Leiomyosarcoma Liposarcoma Synovial Sarcom... Myxofibrosarcom... Angiosarcoma Fibrosarcoma Malignant Perip... Epithelioid Sar...	Dexrazoxane Doxorubicin	18 Years -	Washington University School of Medicine
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma	NCT04480502	Undifferentiate... Myxofibrosarcom...	Envafolimab Ipilimumab	12 Years -	Tracon Pharmaceuticals Inc.
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery	NCT02923778	Leiomyosarcoma Liposarcoma Sarcoma G2 Sarcoma G3 Soft Tissue Sar... Soft Tissue Sar... Stage I Soft Ti... Stage II Soft T... Undifferentiate...	Biopsy Biospecimen Col... Magnetic Resona... Radiation Thera... Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg	NCT04332874	Sarcoma Myxofibrosarcom... Undifferentiate... Alveolar Soft P...	Isolated Limb I... Pembrolizumab infusion of mel...	12 Years -	Memorial Sloan Kettering Cancer Center
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas	NCT04242238	Sarcoma Advanced Sarcom... High Grade Sarc... Leiomyosarcoma Undifferentiate... Myxofibrosarcom... Dedifferentiate...	DCC-3014 Avelumab	18 Years -	Memorial Sloan Kettering Cancer Center
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas	NCT05515068	Osteosarcoma Bone Tumor Bone Sarcoma High Grade Sarc... Osteoblastic Os... Chondroblastic ... Fibroblastic Os... Conventional Os... Conventional Ce... Low Grade Centr... Osseous Sarcoma Osseous Tumor Small Cell Oste... Telangiectatic ... Undifferentiate... Parosteal Osteo... Periosteal Oste... Extraskeletal O... Recurrent Osteo... High Grade Surf... Osseous Angiosa... Osseous Fibrosa... Osseous Leiomyo... Osseous Dediffe... Osseous Mesench... Clear Cell Oste...		-	Klinikum Stuttgart
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma	NCT03425279	Undifferentiate... Myxofibrosarcom...	CAB-AXL-ADC PD-1 inhibitor	12 Years -	BioAtla, Inc.
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas	NCT04242238	Sarcoma Advanced Sarcom... High Grade Sarc... Leiomyosarcoma Undifferentiate... Myxofibrosarcom... Dedifferentiate...	DCC-3014 Avelumab	18 Years -	Memorial Sloan Kettering Cancer Center
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall	NCT03651375	Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito...	Sequential chem... Hypofractionate...	18 Years - 100 Years	Maria Sklodowska-Curie National Research Institute of Oncology

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: